BioVie Inc (BIVI)

[02opida]

RENO, Nev., Nov. 04, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a key opinion leader (KOL) webinar on complications of advanced liver cirrhosis and a clinical trial update on the Phase 2b BIV201 study on Thursday, November 11, 2021, at 1:00pm Eastern Time.

The webinar will feature a presentation by renowned liver disease experts Michael Porayko, M.D., F.A.A.S.L.D., from Vanderbilt Health, and Paolo Angeli, M.D., from University of Padova, Italy. Dr. Porayko will discuss the progression of liver cirrhosis, the typical ascites patient experience, and the unmet medical need for an effective drug therapy. Dr. Angeli will discuss the European experience with terlipressin in the treatment of hepatorenal syndrome – acute kidney injury (HRS-AKI) and continuous infusion dosing of terlipressin compared to IV bolus dosing, referencing published clinical studies.

BioVie’s scientific lead for the company’s Liver Cirrhosis Program, Penelope Markham PhD, will provide an update on the BIV201 (continuous infusion terlipressin) Phase 2b Trial and discuss the scientific basis for the treatment. In the United States, BioVie has Orphan drug and Fast Track designations for the treatment of ascites due to liver cirrhosis. BIV201 also has an Orphan drug designation for treating hepatorenal syndrome (HRS).